The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
Study Rationale: Peptide-based drugs are attractive candidates for treating the cognitive decline associated with Parkinson’s disease (PD) because they demonstrate a robust safety profile and an...
-
[RFA] Use of PD Biosamples - Spring 2020, 2024Neurotoxic Inflammatory Metabolites as Biomarkers of Disease Progression in Parkinson’s Disease
Study Rationale: Individuals with Parkinson’s disease (PD) have inflammation in the brain, cerebrospinal fluid and the blood. We think that inflammation drives the worsening of PD because it increases...
-
Research Grant, 2024Chronos-PD Pilot: Analyzing Plasma from Donors Who Develop Parkinson’s Disease Later in Life
Study Rationale: Our current molecular understanding of Parkinson’s disease (PD) is based on the clinical phase of the disease. However, because PD is a progressive disease, by the time the disorder...
-
Seed Amplification Assay Innovation Program, 2025Quantitative SAA for Measuring Disease Progression in Parkinson’s Disease from Plasma
Study Rationale: Parkinson’s disease (PD) is associated with the accumulation of clumped alpha-synuclein (asyn) protein in the brain. Detecting asyn in blood plasma could provide a less invasive and...
-
Seed Amplification Assay Innovation Program, 2025A Robust, Quantitative SAA and its Clinical Application
Study Rationale: Seed Amplification Assays (SAA) have shown impressive results in distinguishing people with Parkinson's disease from healthy individuals using a simple yes/no test. This test detects...
-
Seed Amplification Assay Innovation Program, 2025Quantitative Real-Time Alpha-synuclein Seed Detection by SeRAS®
Study Rationale: Seed Amplification Assays (SAAs) can detect minute amounts of alpha-synuclein deposits (called seeds) in cerebrospinal fluid (CSF) and other biofluids of Parkinson’s patients. They...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.